Senseonics (NYSE:SENS) Reaches New 52-Week High – What’s Next?

Senseonics Holdings, Inc. (NYSE:SENS)’s share price hit a new 52-week high during mid-day trading on Tuesday . The stock traded as high as $1.20 and last traded at $1.06, with a volume of 18589708 shares. The stock had previously closed at $1.13.

Analysts Set New Price Targets

Several research analysts have issued reports on SENS shares. HC Wainwright reaffirmed a “buy” rating and issued a $2.00 target price on shares of Senseonics in a report on Friday, November 15th. StockNews.com began coverage on shares of Senseonics in a report on Thursday, December 26th. They issued a “sell” rating for the company.

Senseonics Price Performance

The business’s 50 day moving average price is $0.50 and its 200 day moving average price is $0.42. The stock has a market capitalization of $631.05 million, a P/E ratio of -8.15 and a beta of 0.64. The company has a debt-to-equity ratio of 59.17, a current ratio of 2.47 and a quick ratio of 2.38.

Senseonics (NYSE:SENS) last announced its quarterly earnings results on Thursday, November 7th. The company reported ($0.04) EPS for the quarter, missing analysts’ consensus estimates of ($0.03) by ($0.01). Senseonics had a negative return on equity of 842.25% and a negative net margin of 362.30%. The company had revenue of $4.26 million during the quarter, compared to the consensus estimate of $4.02 million. Sell-side analysts forecast that Senseonics Holdings, Inc. will post -0.14 EPS for the current year.

Insider Activity at Senseonics

In other news, CFO Frederick T. Sullivan purchased 124,933 shares of the stock in a transaction on Thursday, December 12th. The shares were acquired at an average price of $0.38 per share, with a total value of $47,474.54. Following the completion of the acquisition, the chief financial officer now directly owns 2,478,844 shares of the company’s stock, valued at $941,960.72. This trade represents a 5.31 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Timothy T. Goodnow purchased 315,000 shares of the stock in a transaction on Tuesday, December 10th. The shares were purchased at an average cost of $0.31 per share, for a total transaction of $97,650.00. Following the acquisition, the chief executive officer now directly owns 11,310,355 shares of the company’s stock, valued at approximately $3,506,210.05. This represents a 2.86 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 3.60% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Senseonics

Large investors have recently added to or reduced their stakes in the company. FMR LLC lifted its holdings in Senseonics by 48,267.2% during the third quarter. FMR LLC now owns 168,318 shares of the company’s stock valued at $59,000 after purchasing an additional 167,970 shares in the last quarter. Geode Capital Management LLC lifted its holdings in Senseonics by 3.2% during the third quarter. Geode Capital Management LLC now owns 5,838,396 shares of the company’s stock valued at $2,042,000 after purchasing an additional 179,103 shares in the last quarter. GSA Capital Partners LLP purchased a new position in Senseonics during the third quarter valued at approximately $117,000. Cubist Systematic Strategies LLC lifted its holdings in shares of Senseonics by 25.9% in the second quarter. Cubist Systematic Strategies LLC now owns 415,404 shares of the company’s stock worth $166,000 after buying an additional 85,501 shares in the last quarter. Finally, Ridgecrest Wealth Partners LLC purchased a new position in shares of Senseonics in the fourth quarter worth $60,000. Hedge funds and other institutional investors own 12.36% of the company’s stock.

About Senseonics

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.